化学療法誘発性好中球減少症の市場：薬剤タイプ、治療タイプ、投与経路、最終用途別-2025-2030年の世界予測

化学療法誘発性好中球減少症市場は、2023年に73億9,000万米ドルと評価され、2024年には77億7,000万米ドルに達すると予測され、CAGR 4.21％で成長し、2030年には98億7,000万米ドルになると予測されています。

化学療法誘発性好中球減少症（CIN）は、化学療法によって好中球が減少することで生じる重大な臨床的懸念です。この副作用は感染症や治療の遅れ、ヘルスケアコストの増加につながるため、慎重なモニタリングと管理が必要です。CIN管理の応用は腫瘍学において不可欠であり、主に顆粒球コロニー刺激因子（G-CSF）のような成長因子、抗生物質、感染リスクを低減しがん治療レジメンの継続を可能にする支持療法手段の使用に重点を置いています。最終用途の範囲には、CINを管理するための革新的な実践を促進する病院、がん治療センター、専門クリニックが含まれます。

CIN管理市場は、がん罹患率の上昇、化学療法使用の増加、支持療法治療の進歩など、いくつかの重要な要因によって牽引されています。最近の動向は、認知度向上プログラムの拡大とともに、バイオシミラー、個別化医療、患者中心のアプローチの開発における潜在的機会を浮き彫りにしています。このような技術革新は、費用対効果の高い代替医療を約束するだけでなく、治療パラダイムの精度に対する需要の高まりにも対応しています。しかし、薬剤費の高騰、低所得地域におけるヘルスケアへのアクセスの制限、現行治療の潜在的な副作用など、成長とアクセシビリティを阻害しかねない市場課題は依然として残っています。

このような機会を活用するため、企業は新規バイオシミラーや次世代G-CSFの研究に注力するとともに、データ解析やAIを統合して介入を調整する必要があります。ヘルスケアプロバイダーとのコラボレーションを重視し、教育イニシアティブに投資することで、市場での存在感と製品採用を高めることができます。しかし、持続的な成長を達成するためには、規制状況を乗り切り、価格競争力を維持することが重要です。CIN管理市場の競争は激しく、急速に進化しているため、継続的なイノベーションと、新たな臨床ニーズや利害関係者の需要への対応が必要です。研究開発と臨床応用の橋渡しを強化することは、このニッチ市場をリードし変革しようとする市場関係者にとって不可欠です。

市場力学：急速に進化する化学療法誘発性好中球減少症市場の主要市場インサイトを公開

化学療法誘発性好中球減少症市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 化学療法の使用量の増加につながるがんの有病率の上昇と、それに伴う好中球減少症の症例の増加
  • 化学療法誘発性好中球減少症に対する認識の高まりと早期診断による患者管理戦略の強化
  • 好中球減少症のリスクを効果的に軽減するための支持療法および成長因子の進歩
  • 化学療法誘発性好中球減少症に対する新規治療法の研究開発を促進する政府とヘルスケアの取り組み
• 市場抑制要因
  • 化学療法における好中球減少症のリスクや治療選択肢に関する患者や医療提供者の認識や教育の欠如
  • 高い治療費と限られた償還オプションが、患者の化学療法誘発性好中球減少症治療へのアクセスを妨げています。
• 市場機会
  • 化学療法誘発性好中球減少症管理における免疫療法とg-CSFを統合した革新的な併用療法
  • 化学療法による好中球減少症の治療を調整するための遺伝子スクリーニングを用いた個別化医療アプローチ
  • 化学療法を受ける好中球減少症患者の遠隔モニタリングと管理のための遠隔医療サービスの拡大
• 市場の課題
  • 化学療法誘発性好中球減少症市場力学に影響を与える経済およびヘルスケア政策の課題
  • 化学療法誘発性好中球減少症管理の進歩を妨げる技術的・インフラ的限界

ポーターの5つの力：化学療法誘発性好中球減少症市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、化学療法誘発性好中球減少症市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：化学療法誘発性好中球減少症市場における外部からの影響の把握

外部マクロ環境要因は、化学療法誘発性好中球減少症市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析化学療法誘発性好中球減少症市場における競合情勢の把握

化学療法誘発性好中球減少症市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス化学療法誘発性好中球減少症市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、化学療法誘発性好中球減少症市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨化学療法誘発性好中球減少症市場における成功への道筋を描く

化学療法誘発性好中球減少症市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がんの罹患率の増加により化学療法の利用が増加し、その結果、誘発性好中球減少症の症例が増加します。
    • 化学療法誘発性好中球減少症の認識の高まりと早期診断により、患者管理戦略が強化される
    • 好中球減少症のリスクを効果的に軽減するための支持療法と成長因子の進歩
    • 化学療法誘発性好中球減少症に対する新しい治療法の研究開発を促進する政府とヘルスケアの取り組み
  • 抑制要因
    • 化学療法における好中球減少症のリスクと治療オプションに関する患者とヘルスケア従事者の認識と教育の欠如
    • 治療費の高さと償還オプションの制限により、患者が化学療法誘発性好中球減少症治療を受けられない
  • 機会
    • 免疫療法とG-CSFを統合した革新的な併用療法化学療法誘発性好中球減少症管理
    • 遺伝子検査を用いて化学療法による好中球減少症の治療法をカスタマイズする個別化医療アプローチ
    • 化学療法を受けている好中球減少症患者の遠隔モニタリングと管理のための遠隔医療サービスの拡大
  • 課題
    • 化学療法誘発性好中球減少症の市場力学に影響を与える経済およびヘルスケア政策の課題
    • 技術面とインフラ面の制限が化学療法誘発性好中球減少症管理の進歩を妨げている
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTLE分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 化学療法誘発性好中球減少症の市場薬の種類別

• 抗生物質
• 抗真菌薬
• 抗ウイルス薬
• コロニー刺激因子
  • フィルグラスチム
  • レノグラスチム
  • ペグフィルグラスチム

第7章 化学療法誘発性好中球減少症の市場治療の種類別

• 治療療法
• 予防療法

第8章 化学療法誘発性好中球減少症の市場：投与経路別

• 注射可能
• オーラル

第9章 化学療法誘発性好中球減少症の市場：最終用途別

• 病院
• 調査・学術機関
• 専門クリニック

第10章 南北アメリカの化学療法誘発性好中球減少症の市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の化学療法誘発性好中球減少症の市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの化学療法誘発性好中球減少症の市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 1. Amgen Inc.
• 2. Apotex Inc.
• 3. Baxter International Inc.
• 4. BeyondSpring Pharmaceuticals
• 5. Biogen Inc.
• 6. Coherus BioSciences
• 7. Dr. Reddy's Laboratories Ltd.
• 8. F. Hoffmann-La Roche AG
• 9. G1 Therapeutics
• 10. Hoffmann-La Roche Ltd.
• 11. Kiadis Pharma
• 12. Mylan N.V.
• 13. Novartis AG
• 14. OncoGenerix USA Inc.
• 15. Pfizer Inc.
• 16. Sandoz International GmbH
• 17. Sanofi S.A.
• 18. Sun Pharmaceutical Industries Ltd.
• 19. Teva Pharmaceutical Industries Ltd.
• 20. Zydus Cadila

LIST OF FIGURES

• FIGURE 1. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET RESEARCH PROCESS
• FIGURE 2. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET DYNAMICS
• TABLE 7. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY LENOGRASTIM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY CURATIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PROPHYLACTIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 42. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 43. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 44. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 45. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 69. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 70. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 71. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 72. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 74. INDIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 75. INDIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 76. INDIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 77. INDIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. INDIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 89. MALAYSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 94. PHILIPPINES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 99. SINGAPORE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 104. SOUTH KOREA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 109. TAIWAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 114. THAILAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 119. VIETNAM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 130. DENMARK CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 135. EGYPT CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 140. FINLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 145. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 150. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 155. ISRAEL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 160. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 161. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 162. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 163. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 165. NETHERLANDS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 170. NIGERIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 175. NORWAY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 180. POLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 181. POLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 182. POLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 183. POLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 184. POLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 185. QATAR CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 186. QATAR CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 187. QATAR CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 188. QATAR CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 189. QATAR CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 190. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 195. SAUDI ARABIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 205. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 210. SWEDEN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 215. SWITZERLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 220. TURKEY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 225. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 230. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 235. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 236. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET, FPNV POSITIONING MATRIX, 2023

The Chemotherapy Induced Neutropenia Market was valued at USD 7.39 billion in 2023, expected to reach USD 7.77 billion in 2024, and is projected to grow at a CAGR of 4.21%, to USD 9.87 billion by 2030.

Chemotherapy Induced Neutropenia (CIN) is a significant clinical concern that occurs when chemotherapy reduces neutrophils, vital white blood cells critical for fighting infections. This adverse effect necessitates careful monitoring and management as it can lead to infections, treatment delays, and increased healthcare costs. The application of CIN management is essential in oncology, primarily focusing on the use of growth factors like granulocyte colony-stimulating factors (G-CSFs), antibiotics, and supportive care measures to reduce infection risks and enable continuance of cancer treatment regimens. The end-use scope encompasses hospitals, cancer treatment centers, and specialty clinics fostering innovative practices for managing CIN.

The market for CIN management is driven by several key factors, including the rising prevalence of cancer, increasing chemotherapy usage, and advancements in supportive care treatments. Recent trends highlight the potential opportunities in the development of biosimilars, personalized medicine, and patient-centric approaches, alongside expanding awareness programs. Such innovations not only promise cost-effective alternatives but also cater to growing demands for precision in treatment paradigms. However, market challenges persist, including high drug costs, limited access to healthcare in low-income regions, and potential side effects of current treatments, which could hinder growth and accessibility.

To capitalize on these opportunities, companies should focus on research into novel biosimilars and next-generation G-CSFs, alongside integrating data analytics and AI to tailor interventions. Emphasizing collaborations with healthcare providers and investing in educational initiatives can enhance market presence and product adoption. However, navigating regulatory landscapes and maintaining price competitiveness are critical to attaining sustained growth. The nature of the CIN management market is highly competitive and rapidly evolving, necessitating continuous innovation and responsiveness to emerging clinical needs and stakeholder demands. Strengthening the bridge between R&D and clinical application will be imperative for market players aspiring to lead and transform this niche's landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chemotherapy Induced Neutropenia Market

The Chemotherapy Induced Neutropenia Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of cancer leading to higher chemotherapy usage and subsequent rise in cases of induced neutropenia
  • Growing awareness and early diagnosis of chemotherapy-induced neutropenia enhancing patient management strategies
  • Advancements in supportive care therapies and growth factors to effectively mitigate neutropenia risks
  • Government and healthcare initiatives promoting research and development of novel treatments for chemotherapy-induced neutropenia
• Market Restraints
  • Lack of awareness and education among patients and healthcare providers regarding neutropenia risks and treatment options in chemotherapy
  • High treatment costs and limited reimbursement options hindering patient access to chemotherapy induced neutropenia therapies
• Market Opportunities
  • Innovative combination therapies integrating immunotherapy and g-csf in chemotherapy induced neutropenia management
  • Personalized medicine approaches using genetic screening to tailor treatments for neutropenia caused by chemotherapy
  • Expansion of telehealth services for remote monitoring and management of neutropenic patients undergoing chemotherapy
• Market Challenges
  • Economic and healthcare policy challenges impacting chemotherapy induced neutropenia market dynamics
  • Technological and infrastructure limitations hindering advancements in chemotherapy induced neutropenia management

Porter's Five Forces: A Strategic Tool for Navigating the Chemotherapy Induced Neutropenia Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chemotherapy Induced Neutropenia Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chemotherapy Induced Neutropenia Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chemotherapy Induced Neutropenia Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chemotherapy Induced Neutropenia Market

A detailed market share analysis in the Chemotherapy Induced Neutropenia Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chemotherapy Induced Neutropenia Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chemotherapy Induced Neutropenia Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chemotherapy Induced Neutropenia Market

A strategic analysis of the Chemotherapy Induced Neutropenia Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chemotherapy Induced Neutropenia Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Apotex Inc., Baxter International Inc., BeyondSpring Pharmaceuticals, Biogen Inc., Coherus BioSciences, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, G1 Therapeutics, Hoffmann-La Roche Ltd., Kiadis Pharma, Mylan N.V., Novartis AG, OncoGenerix USA Inc., Pfizer Inc., Sandoz International GmbH, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Zydus Cadila.

Market Segmentation & Coverage

This research report categorizes the Chemotherapy Induced Neutropenia Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type of Drug, market is studied across Antibiotics, Antifungals, Antivirals, and Colony Stimulating Factor. The Colony Stimulating Factor is further studied across Filgrastim, Lenograstim, and Pegfilgrastim.
• Based on Treatment Type, market is studied across Curative Therapy and Prophylactic Therapy.
• Based on Route of Administration, market is studied across Injectable and Oral.
• Based on End-Use, market is studied across Hospitals, Research and Academic Institutes, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of cancer leading to higher chemotherapy usage and subsequent rise in cases of induced neutropenia
    • 5.1.1.2. Growing awareness and early diagnosis of chemotherapy-induced neutropenia enhancing patient management strategies
    • 5.1.1.3. Advancements in supportive care therapies and growth factors to effectively mitigate neutropenia risks
    • 5.1.1.4. Government and healthcare initiatives promoting research and development of novel treatments for chemotherapy-induced neutropenia
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of awareness and education among patients and healthcare providers regarding neutropenia risks and treatment options in chemotherapy
    • 5.1.2.2. High treatment costs and limited reimbursement options hindering patient access to chemotherapy induced neutropenia therapies
  • 5.1.3. Opportunities
    • 5.1.3.1. Innovative combination therapies integrating immunotherapy and g-csf in chemotherapy induced neutropenia management
    • 5.1.3.2. Personalized medicine approaches using genetic screening to tailor treatments for neutropenia caused by chemotherapy
    • 5.1.3.3. Expansion of telehealth services for remote monitoring and management of neutropenic patients undergoing chemotherapy
  • 5.1.4. Challenges
    • 5.1.4.1. Economic and healthcare policy challenges impacting chemotherapy induced neutropenia market dynamics
    • 5.1.4.2. Technological and infrastructure limitations hindering advancements in chemotherapy induced neutropenia management
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Chemotherapy Induced Neutropenia Market, by Type of Drug

• 6.1. Introduction
• 6.2. Antibiotics
• 6.3. Antifungals
• 6.4. Antivirals
• 6.5. Colony Stimulating Factor
  • 6.5.1. Filgrastim
  • 6.5.2. Lenograstim
  • 6.5.3. Pegfilgrastim

7. Chemotherapy Induced Neutropenia Market, by Treatment Type

• 7.1. Introduction
• 7.2. Curative Therapy
• 7.3. Prophylactic Therapy

8. Chemotherapy Induced Neutropenia Market, by Route of Administration

• 8.1. Introduction
• 8.2. Injectable
• 8.3. Oral

9. Chemotherapy Induced Neutropenia Market, by End-Use

• 9.1. Introduction
• 9.2. Hospitals
• 9.3. Research and Academic Institutes
• 9.4. Specialty Clinics

10. Americas Chemotherapy Induced Neutropenia Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Chemotherapy Induced Neutropenia Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Chemotherapy Induced Neutropenia Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amgen Inc.
• 2. Apotex Inc.
• 3. Baxter International Inc.
• 4. BeyondSpring Pharmaceuticals
• 5. Biogen Inc.
• 6. Coherus BioSciences
• 7. Dr. Reddy's Laboratories Ltd.
• 8. F. Hoffmann-La Roche AG
• 9. G1 Therapeutics
• 10. Hoffmann-La Roche Ltd.
• 11. Kiadis Pharma
• 12. Mylan N.V.
• 13. Novartis AG
• 14. OncoGenerix USA Inc.
• 15. Pfizer Inc.
• 16. Sandoz International GmbH
• 17. Sanofi S.A.
• 18. Sun Pharmaceutical Industries Ltd.
• 19. Teva Pharmaceutical Industries Ltd.
• 20. Zydus Cadila